Brief: Elicio Therapeutics Reports Results From Phase 2 AMPLIFY-7P Study And Outlines Refined Phase 3 Development Strategy For ELI-002 7P In Adjuvant Pancreatic Cancer
15/06/2026 12:20
BRIEF-Elicio Therapeutics Reports Results From Phase 2 AMPLIFY-7P Study And Outlines Refined Phase 3 Development Strategy For ELI-002 7P In Adjuvant Pancreatic Cancer June 15 (Reuters) - Elicio Therapeutics Inc ELTX.O:
ELICIO THERAPEUTICS REPORTS RESULTS FROM PHASE 2 AMPLIFY-7P STUDY AND OUTLINES REFINED PHASE 3 DEVELOPMENT STRATEGY FOR ELI-002 7P IN ADJUVANT PANCREATIC CANCER
ELICIO THERAPEUTICS - AMPLIFY-7P PHASE 2 STUDY DOES NOT MEET PRIMARY DFS ENDPOINT IN INTENT-TO-TREAT POPULATION
ELICIO THERAPEUTICS - ELI-2 7P DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
ELICIO THERAPEUTICS - EVALUATING STRATEGIC FINANCING AND PARTNERING OPPORTUNITIES
ELICIO THERAPEUTICS - TO FOCUS PHASE 3 DEVELOPMENT ON R0 RESECTED POPULATION WITH ADDITIONAL ELI-2 7P DOSING
Source text: ID:nGNXbVchpw
Further company coverage: ELTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)